| Product Name | Netupitant - API |
| Product Code | DA-N097-a |
| Chemical name | Netupitant |
| Synonyms | 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide; 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide; |
| Impurity | NA |
| CAS Number | 290297-26-6 |
| Alternate CAS # | NA |
| Molecular form | C30H32F6N4O |
| Appearance | White to Off-White Solid |
| Melting Point | NA |
| Mol. Weight | 578.6 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,fine chemicals |
| Boiling Point | NA |
| Applications | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics under the brand Akynzeo. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
